{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:43:17Z","timestamp":1790833397059,"version":"4.1.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:00:00Z","timestamp":1601424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:00:00Z","timestamp":1601424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Jichi Medical University Young Investigator Award"},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["15H05654"],"award-info":[{"award-number":["15H05654"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K08960"],"award-info":[{"award-number":["19K08960"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18K15149"],"award-info":[{"award-number":["18K15149"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17K15691"],"award-info":[{"award-number":["17K15691"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17K19570"],"award-info":[{"award-number":["17K19570"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP17fm0208028"],"award-info":[{"award-number":["JP17fm0208028"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP18fm0208028"],"award-info":[{"award-number":["JP18fm0208028"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19fm0208028"],"award-info":[{"award-number":["JP19fm0208028"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20fk0108134"],"award-info":[{"award-number":["JP20fk0108134"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We first reported a phenomenon of cross-resistance to vancomycin (VCM) and daptomycin (DAP) in methicillin-resistant\n                    <jats:italic>Staphylococcus aureus<\/jats:italic>\n                    (MRSA) in 2006, but mechanisms underlying the cross-resistance remain incompletely understood. Here, we present a follow-up study aimed to investigate genetic determinants associated with the cross-resistance. Using 12 sets of paired DAP susceptible (DAP\n                    <jats:sup>S<\/jats:sup>\n                    ) and DAP non-susceptible (DAP\n                    <jats:sup>R<\/jats:sup>\n                    ) MRSA isolates from 12 patients who had DAP therapy, we (i) assessed susceptibility to DAP and VCM, (ii) compared whole-genome sequences, (iii) identified mutations associated with cross-resistance to DAP and VCM, and (iv) investigated the impact of altered gene expression and metabolic pathway relevant to the cross-resistance. We found that all 12 DAP\n                    <jats:sup>R<\/jats:sup>\n                    strains exhibiting cross-resistance to DAP and VCM carried mutations in\n                    <jats:italic>mprF<\/jats:italic>\n                    , while one DAP\n                    <jats:sup>R<\/jats:sup>\n                    strain with reduced susceptibility to only DAP carried a\n                    <jats:italic>lacF<\/jats:italic>\n                    mutation. On the other hand, among the 32 vancomycin-intermediate\n                    <jats:italic>S. aureus<\/jats:italic>\n                    (VISA) strains isolated from patients treated with VCM, five out of the 18 strains showing cross-resistance to DAP and VCM carried a\n                    <jats:italic>mprF<\/jats:italic>\n                    mutation, while 14 strains resistant to only VCM had no\n                    <jats:italic>mprF<\/jats:italic>\n                    mutation. Moreover, substitution of\n                    <jats:italic>mprF<\/jats:italic>\n                    in a DAP\n                    <jats:sup>S<\/jats:sup>\n                    strain with mutated\n                    <jats:italic>mprF<\/jats:italic>\n                    resulted in cross-resistance and vice versa. The elevated lysyl-phosphatidylglycerol (L-PG) production, increased positive bacterial surface charges and activated cell wall (CW) synthetic pathways were commonly found in both clinical isolates and laboratory-developed mutants that carry\n                    <jats:italic>mprF<\/jats:italic>\n                    mutations. We conclude that\n                    <jats:italic>mprF<\/jats:italic>\n                    mutation is responsible for the cross-resistance of MRSA to DAP and VCM, and treatment with DAP is more likely to select for\n                    <jats:italic>mprF<\/jats:italic>\n                    -mediated cross-resistance than is with VCM.\n                  <\/jats:p>","DOI":"10.1038\/s41598-020-73108-x","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T06:05:26Z","timestamp":1601445926000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Association of mprF mutations with cross-resistance to daptomycin and vancomycin in methicillin-resistant Staphylococcus aureus (MRSA)"],"prefix":"10.1038","volume":"10","author":[{"given":"Kanate","family":"Thitiananpakorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Aiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Ee","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Kiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Sato\u2019o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanit","family":"Boonsiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Yu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teppei","family":"Sasahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Taki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aa Haeruman","family":"Azam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuancheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longzhu","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,30]]},"reference":[{"key":"73108_CR1","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2217\/17460913.2.3.323","volume":"2","author":"A Pantosti","year":"2007","unstructured":"Pantosti, A., Sanchini, A. & Monaco, M. Mechanisms of antibiotic resistance in Staphylococcus aureus. Future Microbiol. 2, 323\u2013334 (2007).","journal-title":"Future Microbiol."},{"issue":"Suppl 2","key":"73108_CR2","first-page":"ii65","volume":"62","author":"R Hope","year":"2008","unstructured":"Hope, R. et al. Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001\u201306. J. Antimicrob. Chemother. 62(Suppl 2), ii65\u2013ii74 (2008).","journal-title":"J. Antimicrob. Chemother."},{"key":"73108_CR3","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1016\/S0002-9343(98)00149-1","volume":"104","author":"K Hiramatsu","year":"1998","unstructured":"Hiramatsu, K. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. Am. J. Med. 104, 7S-10S (1998).","journal-title":"Am. J. Med."},{"key":"73108_CR4","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/jac\/45.6.887","volume":"45","author":"O Chesneau","year":"2000","unstructured":"Chesneau, O., Morvan, A. & Solh, N. E. Retrospective screening for heterogeneous vancomycin resistance in diverse Staphylococcus aureus clones disseminated in French hospitals. J. Antimicrob. Chemother. 45, 887\u2013890 (2000).","journal-title":"J. Antimicrob. Chemother."},{"issue":"Suppl D","key":"73108_CR5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/jac\/14.suppl_D.7","volume":"14","author":"C Watanakunakorn","year":"1984","unstructured":"Watanakunakorn, C. Mode of action and in-vitro activity of vancomycin. J. Antimicrob. Chemother. 14(Suppl D), 7\u201318 (1984).","journal-title":"J. Antimicrob. Chemother."},{"key":"73108_CR6","first-page":"1113","volume":"90","author":"V Ferraz","year":"2000","unstructured":"Ferraz, V. et al. Vancomycin-resistant Staphylococcus aureus occurs in South Africa. S. Afr. Med. J. 90, 1113 (2000).","journal-title":"S. Afr. Med. J."},{"key":"73108_CR7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1128\/JCM.41.1.5-14.2003","volume":"41","author":"L Cui","year":"2003","unstructured":"Cui, L. et al. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J. Clin. Microbiol. 41, 5\u201314 (2003).","journal-title":"J. Clin. Microbiol."},{"key":"73108_CR8","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1128\/AAC.50.2.428-438.2006","volume":"50","author":"L Cui","year":"2006","unstructured":"Cui, L. et al. Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents. Chemother. 50, 428\u2013438 (2006).","journal-title":"Antimicrob. Agents. Chemother."},{"key":"73108_CR9","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/MCC.0b013e32832f0a74","volume":"15","author":"ME Stryjewski","year":"2009","unstructured":"Stryjewski, M. E. & Corey, G. R. New treatments for methicillin-resistant Staphylococcus aureus. Curr. Opin. Crit Care. 15, 403\u2013412 (2009).","journal-title":"Curr. Opin. Crit Care."},{"key":"73108_CR10","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.bbamem.2011.01.001","volume":"1808","author":"JK Muraih","year":"2011","unstructured":"Muraih, J. K., Pearson, A., Silverman, J. & Palmer, M. Oligomerization of daptomycin on membranes. Biochim. Biophys. Acta 1808, 1154\u20131160 (2011).","journal-title":"Biochim. Biophys. Acta"},{"key":"73108_CR11","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.chembiol.2004.04.020","volume":"11","author":"D Jung","year":"2004","unstructured":"Jung, D., Rozek, A., Okon, M. & Hancock, R. E. Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin. Chem. Biol. 11, 949\u2013957 (2004).","journal-title":"Chem. Biol."},{"key":"73108_CR12","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/ajhp\/62.11.1145","volume":"62","author":"CA Schriever","year":"2005","unstructured":"Schriever, C. A., Fern\u00e1ndez, C., Rodvold, K. A. & Danziger, L. H. Daptomycin: a novel cyclic lipopeptide antimicrobial. Am. J. Health Syst. Pharm. 62, 1145\u20131158 (2005).","journal-title":"Am. J. Health Syst. Pharm."},{"key":"73108_CR13","first-page":"e102","volume":"5","author":"CM Ernst","year":"2009","unstructured":"Ernst, C. M. et al. The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion. PLoSPathog. 5, e102 (2009).","journal-title":"PLoSPathog."},{"key":"73108_CR14","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1128\/AAC.50.3.1079-1082.2006","volume":"50","author":"L Cui","year":"2006","unstructured":"Cui, L., Tominaga, E., Neoh, H. M. & Hiramatsu, K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50, 1079\u20131082 (2006).","journal-title":"Antimicrob. Agents Chemother."},{"key":"73108_CR15","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1128\/AAC.50.4.1581-1585.2006","volume":"50","author":"G Sakoulas","year":"2006","unstructured":"Sakoulas, G., Alder, J., Thauvin-Eliopoulos, C., Moellering, R. C. & Eliopoulos, G. M. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob. Agents Chemother. 50, 1581\u20131585 (2006).","journal-title":"Antimicrob. Agents Chemother."},{"key":"73108_CR16","doi-asserted-by":"crossref","first-page":"4800","DOI":"10.1128\/AAC.48.12.4800-4807.2004","volume":"48","author":"H Nishi","year":"2004","unstructured":"Nishi, H., Komatsuzawa, H., Fujiwara, T., McCallum, N. & Sugai, M. Reduced content of lysyl-phosphatidylglycerol in the cytoplasmic membrane affects susceptibility to moenomycin, as well as vancomycin, gentamicin, and antimicrobial peptides, Staphylococcus aureus. Antimicrob. Agents Chemother. 48, 4800\u20134807 (2004).","journal-title":"Antimicrob. Agents Chemother."},{"key":"73108_CR17","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1128\/AAC.00039-06","volume":"50","author":"L Friedman","year":"2006","unstructured":"Friedman, L., Alder, J. D. & Silverman, J. A. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob. Agents Chemother. 50, 2137\u20132145 (2006).","journal-title":"Antimicrob. Agents Chemother."},{"key":"73108_CR18","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1128\/AAC.01415-08","volume":"53","author":"SJ Yang","year":"2009","unstructured":"Yang, S. J. et al. Regulation of mprF in daptomycin-nonsusceptible Staphylococcus aureus strains. Antimicrob. Agents Chemother. 53, 2636\u20132637 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"key":"73108_CR19","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1128\/AAC.00370-12","volume":"56","author":"CJ Slavetinsky","year":"2012","unstructured":"Slavetinsky, C. J., Peschel, A. & Ernst, C. M. Alanyl-phosphatidylglycerol and lysyl-phosphatidylglycerol are translocated by the same MprF flippases and have similar capacities to protect against the antibiotic daptomycin in Staphylococcus aureus. Antimicrob. Agents Chemother. 56, 3492\u20133497 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"73108_CR20","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1093\/jac\/dkw142","volume":"71","author":"AS Bayer","year":"2016","unstructured":"Bayer, A. S., Mishra, N. N., Cheung, A. L., Rubio, A. & Yang, S. J. Dysregulation of mprF and dltABCD expression among daptomycin-non-susceptible MRSA clinical isolates. J. Antimicrob. Chemother. 71, 2100\u20132104 (2016).","journal-title":"J. Antimicrob. Chemother."},{"key":"73108_CR21","doi-asserted-by":"crossref","first-page":"e02340","DOI":"10.1128\/mBio.02340-14","volume":"6","author":"CM Ernst","year":"2015","unstructured":"Ernst, C. M. et al. The lipid-modifying multiple peptide resistance factor is an oligomer consisting of distinct interacting synthase and flippase subunits. MBio 6, e02340 (2015).","journal-title":"MBio"},{"key":"73108_CR22","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1128\/AAC.01184-13","volume":"57","author":"SJ Yang","year":"2013","unstructured":"Yang, S. J., Mishra, N. N., Rubio, A. & Bayer, A. S. Causal role of single nucleotide polymorphisms within the mprF gene of Staphylococcus aureus in daptomycin resistance. Antimicrob. Agents Chemother. 57, 5658\u20135664 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"73108_CR23","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1128\/AAC.00970-15","volume":"59","author":"AS Bayer","year":"2015","unstructured":"Bayer, A. S. et al. Frequency and distribution of single-nucleotide polymorphisms within mprF in methicillin-Resistant Staphylococcus aureus clinical isolates and their role in cross-resistance to daptomycin and host defense antimicrobial peptides. Antimicrob. Agents Chemother. 59, 4930\u20134937 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"73108_CR24","doi-asserted-by":"crossref","first-page":"e71151","DOI":"10.1371\/journal.pone.0071151","volume":"8","author":"NN Mishra","year":"2013","unstructured":"Mishra, N. N. et al. Emergence of daptomycin resistance in daptomycin-na\u00efve rabbits with methicillin-resistant Staphylococcus aureus prosthetic joint infection is associated with resistance to host defense cationic peptides and mprF polymorphisms. PLoS ONE 8, e71151 (2013).","journal-title":"PLoS ONE"},{"key":"73108_CR25","first-page":"e00802","volume":"9","author":"CM Ernst","year":"2018","unstructured":"Ernst, C. M. et al. Gain-of-function mutations in the phospholipid flippasemprF confer specific daptomycin resistance. MBio 9, e00802 (2018).","journal-title":"MBio"},{"key":"73108_CR26","doi-asserted-by":"crossref","first-page":"e67398","DOI":"10.1371\/journal.pone.0067398","volume":"8","author":"U Bertsche","year":"2013","unstructured":"Bertsche, U. et al. Increased cell wall teichoic acid production and D-alanylation are common phenotypes among daptomycin-resistant methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates. PLoS ONE 8, e67398 (2013).","journal-title":"PLoS ONE"},{"key":"73108_CR27","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1099\/mic.0.26426-0","volume":"149","author":"S Utaida","year":"2003","unstructured":"Utaida, S. et al. Genome-wide transcriptional profiling of the response of Staphylococcus aureus to cell-wall-active antibiotics reveals a cell-wall-stress stimulon. Microbiology 149, 2719\u20132732 (2003).","journal-title":"Microbiology"},{"key":"73108_CR28","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1046\/j.1365-2958.2003.03599.x","volume":"49","author":"M Kuroda","year":"2003","unstructured":"Kuroda, M. et al. Two-component system VraSR positively modulates the regulation of cell-wall biosynthesis pathway in Staphylococcus aureus. Mol Microbiol 49, 807\u2013821 (2003).","journal-title":"Mol Microbiol"},{"key":"73108_CR29","doi-asserted-by":"crossref","first-page":"e00557","DOI":"10.1128\/mSphere.00557-18","volume":"4","author":"A Taglialegna","year":"2019","unstructured":"Taglialegna, A., Varela, M. C., Rosato, R. R. & Rosato, A. E. VraSR and virulence trait modulation during daptomycin resistance in methicillin-resistant. mSphere 4, e00557 (2019).","journal-title":"mSphere"},{"key":"73108_CR30","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1128\/AAC.01563-10","volume":"55","author":"M Shoji","year":"2011","unstructured":"Shoji, M. et al. walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus. Antimicrob. Agents Chemother. 55, 3870\u20133881 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"key":"73108_CR31","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1128\/AAC.00122-10","volume":"54","author":"SJ Yang","year":"2010","unstructured":"Yang, S. J. et al. Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms. Antimicrob. Agents Chemother. 54, 3079\u20133085 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"73108_CR32","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0167-4781(00)00012-9","volume":"1490","author":"M Yarmus","year":"2000","unstructured":"Yarmus, M., Mett, A. & Shapira, R. Cloning and expression of the genes involved in the production of and immunity against the bacteriocinlacticin RM. Biochim. Biophys. Acta 1490, 279\u2013290 (2000).","journal-title":"Biochim. Biophys. Acta"},{"key":"73108_CR33","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1128\/AAC.01139-12","volume":"56","author":"C Hafer","year":"2012","unstructured":"Hafer, C., Lin, Y., Kornblum, J., Lowy, F. D. & Uhlemann, A. C. Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 56, 5845\u20135851 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"73108_CR34","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1128\/JCM.02144-10","volume":"49","author":"Y Watanabe","year":"2011","unstructured":"Watanabe, Y., Cui, L., Katayama, Y., Kozue, K. & Hiramatsu, K. Impact of rpoB mutations on reduced vancomycin susceptibility in Staphylococcus aureus. J. Clin. Microbiol. 49, 2680\u20132684 (2011).","journal-title":"J. Clin. Microbiol."},{"key":"73108_CR35","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1128\/AAC.00437-10","volume":"54","author":"L Cui","year":"2010","unstructured":"Cui, L. et al. An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus. Antimicrob. Agents Chemother. 54, 5222\u20135233 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"73108_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jiac.2018.09.009","volume":"25","author":"I Kanesaka","year":"2019","unstructured":"Kanesaka, I. et al. Characterization of compensatory mutations associated with restoration of daptomycin-susceptibility in daptomycin non-susceptible methicillin-resistant Staphylococcus aureus and the role mprF mutations. J. Infect. Chemother. 25, 1\u20135 (2019).","journal-title":"J. Infect. Chemother."},{"key":"73108_CR37","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1128\/JCM.41.4.1687-1693.2003","volume":"41","author":"K Sieradzki","year":"2003","unstructured":"Sieradzki, K., Leski, T., Dick, J., Borio, L. & Tomasz, A. Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for chemotherapy. J. Clin. Microbiol. 41, 1687\u20131693 (2003).","journal-title":"J. Clin. Microbiol."},{"key":"73108_CR38","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1128\/JB.01345-08","volume":"191","author":"S Samant","year":"2009","unstructured":"Samant, S., Hsu, F. F., Neyfakh, A. A. & Lee, H. The Bacillus anthracis protein MprF is required for synthesis of lysylphosphatidylglycerols and for resistance to cationic antimicrobial peptides. J. Bacteriol. 191, 1311\u20131319 (2009).","journal-title":"J. Bacteriol."},{"key":"73108_CR39","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1128\/AAC.00719-07","volume":"52","author":"T Jones","year":"2008","unstructured":"Jones, T. et al. Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob. Agents Chemother. 52, 269\u2013278 (2008).","journal-title":"Antimicrob. Agents Chemother."},{"key":"73108_CR40","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1128\/AAC.00191-10","volume":"54","author":"E Kilelee","year":"2010","unstructured":"Kilelee, E., Pokorny, A., Yeaman, M. R. & Bayer, A. S. Lysyl-phosphatidylglycerol attenuates membrane perturbation rather than surface association of the cationic antimicrobial peptide 6W-RP-1 in a model membrane system: implications for daptomycin resistance. Antimicrob. Agents Chemother. 54, 4476\u20134479 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"73108_CR41","doi-asserted-by":"crossref","first-page":"9910","DOI":"10.1074\/jbc.275.14.9910","volume":"275","author":"IG Boneca","year":"2000","unstructured":"Boneca, I. G., Huang, Z. H., Gage, D. A. & Tomasz, A. Characterization of Staphylococcus aureus cell wall glycan strands, evidence for a new beta-N-acetylglucosaminidase activity. J. Biol. Chem. 275, 9910\u20139918 (2000).","journal-title":"J. Biol. Chem."},{"key":"73108_CR42","first-page":"145","volume":"409","author":"AF Haag","year":"2017","unstructured":"Haag, A. F. & Bagnoli, F. The role of two-component signal transduction systems in Staphylococcus aureus virulence regulation. Curr. Top. Microbiol. Immunol. 409, 145\u2013198 (2017).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"73108_CR43","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1038\/s41467-019-13127-z","volume":"10","author":"EA Libby","year":"2019","unstructured":"Libby, E. A., Reuveni, S. & Dworkin, J. Multisite phosphorylation drives phenotypic variation in (p)ppGpp synthetase-dependent antibiotic tolerance. Nat. Commun. 10, 5133 (2019).","journal-title":"Nat. Commun."},{"key":"73108_CR44","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0304-4165(03)00028-X","volume":"1621","author":"A Ruzin","year":"2003","unstructured":"Ruzin, A. et al. Inactivation of mprF affects vancomycin susceptibility in Staphylococcus aureus. Biochim. Biophys. Acta 1621, 117\u2013121 (2003).","journal-title":"Biochim. Biophys. Acta"},{"key":"73108_CR45","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.3389\/fmicb.2018.02705","volume":"9","author":"AJ Sabat","year":"2018","unstructured":"Sabat, A. J. et al. Daptomycin resistant Staphylococcus aureus clinical strain with novel non-synonymous mutations in the mprF and vraS genes: a new insight into daptomycin resistance. Front Microbiol. 9, 2705 (2018).","journal-title":"Front Microbiol."},{"key":"73108_CR46","doi-asserted-by":"crossref","first-page":"e28316","DOI":"10.1371\/journal.pone.0028316","volume":"7","author":"AY Peleg","year":"2012","unstructured":"Peleg, A. Y. et al. Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus. PLoS ONE 7, e28316 (2012).","journal-title":"PLoS ONE"},{"key":"73108_CR47","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.3389\/fmicb.2017.02303","volume":"8","author":"M Roch","year":"2017","unstructured":"Roch, M. et al. Daptomycin resistance in clinical MRSA strains is associated with a high biological fitness cost. Front Microbiol. 8, 2303 (2017).","journal-title":"Front Microbiol."},{"key":"73108_CR48","first-page":"e00281","volume":"4","author":"TT Tran","year":"2013","unstructured":"Tran, T. T. et al. Daptomycin-resistant Enterococcus faecalis diverts the antibiotic molecule from the division septum and remodels cell membrane phospholipids. MBio 4, e00281 (2013).","journal-title":"MBio"},{"key":"73108_CR49","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1128\/AAC.00687-16","volume":"60","author":"SA Hall","year":"2016","unstructured":"Hall, S. A. et al. Fosfomycin enhances the activity of daptomycin against vancomycin-resistant Enterococci in an in vitro pharmacokinetic-pharmacodynamic model. Antimicrob. Agents Chemother. 60, 5716\u20135723 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"key":"73108_CR50","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1517\/13543784.8.8.1223","volume":"8","author":"FP Tally","year":"1999","unstructured":"Tally, F. P. et al. Daptomycin: a novel agent for Gram-positive infections. Expert Opin. Investig. Drugs 8, 1223\u20131238 (1999).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"73108_CR51","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1128\/AAC.44.4.1062-1066.2000","volume":"44","author":"MJ Rybak","year":"2000","unstructured":"Rybak, M. J., Hershberger, E., Moldovan, T. & Grucz, R. G. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains. Antimicrob. Agents Chemother. 44, 1062\u20131066 (2000).","journal-title":"Antimicrob. Agents Chemother."},{"key":"73108_CR52","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1038\/s41467-020-15257-1","volume":"11","author":"F Grein","year":"2020","unstructured":"Grein, F. et al. Ca2+-Daptomycin targets cell wall biosynthesis by forming a tripartite complex with undecaprenyl-coupled intermediates and membrane lipids. Nat. Commun. 11, 1455 (2020).","journal-title":"Nat. Commun."},{"key":"73108_CR53","first-page":"E5","volume":"7","author":"JL Johnson","year":"2006","unstructured":"Johnson, J. L. & Yalkowsky, S. H. Reformulation of a new vancomycin analog: an example of the importance of buffer species and strength. AAPS PharmSciTech 7, E5 (2006).","journal-title":"AAPS PharmSciTech"},{"key":"73108_CR54","doi-asserted-by":"crossref","first-page":"e0146401","DOI":"10.1371\/journal.pone.0146401","volume":"11","author":"CT Gustafson","year":"2016","unstructured":"Gustafson, C. T. et al. Controlled delivery of vancomycin via charged hydrogels. PLoS ONE 11, e0146401 (2016).","journal-title":"PLoS ONE"},{"key":"73108_CR55","doi-asserted-by":"crossref","first-page":"8405","DOI":"10.1074\/jbc.274.13.8405","volume":"274","author":"A Peschel","year":"1999","unstructured":"Peschel, A. et al. Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J. Biol. Chem. 274, 8405\u20138410 (1999).","journal-title":"J. Biol. Chem."},{"key":"73108_CR56","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1128\/AAC.44.10.2845-2847.2000","volume":"44","author":"A Peschel","year":"2000","unstructured":"Peschel, A., Vuong, C., Otto, M. & G\u00f6tz, F. The D-alanine residues of Staphylococcus aureus teichoic acids alter the susceptibility to vancomycin and the activity of autolytic enzymes. Antimicrob. Agents. Chemother. 44, 2845\u20132847 (2000).","journal-title":"Antimicrob. Agents. Chemother."},{"key":"73108_CR57","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0378-1097(03)00921-2","volume":"231","author":"P Staubitz","year":"2004","unstructured":"Staubitz, P., Neumann, H., Schneider, T., Wiedemann, I. & Peschel, A. MprF-mediated biosynthesis of lysylphosphatidylglycerol, an important determinant in staphylococcal defensin resistance. FEMS Microbiol. Lett. 231, 67\u201371 (2004).","journal-title":"FEMS Microbiol. Lett."},{"key":"73108_CR58","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s12275-017-6509-1","volume":"55","author":"KM Kang","year":"2017","unstructured":"Kang, K. M. et al. Phenotypic and genotypic correlates of daptomycin-resistant methicillin-susceptible Staphylococcus aureus clinical isolates. J. Microbiol. 55, 153\u2013159 (2017).","journal-title":"J. Microbiol."},{"key":"73108_CR59","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1182\/blood-2012-03-419747","volume":"120","author":"B Everts","year":"2012","unstructured":"Everts, B. et al. Commitment to glycolysis sustains survival of NO-producing inflammatory dendritic cells. Blood 120, 1422\u20131431. https:\/\/doi.org\/10.1182\/blood-2012-03-419747 (2012).","journal-title":"Blood"},{"key":"73108_CR60","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02272-17","author":"L Harper","year":"2018","unstructured":"Harper, L. et al. Responds to the central metabolite pyruvate to regulate virulence. MBio https:\/\/doi.org\/10.1128\/mBio.02272-17 (2018).","journal-title":"MBio"},{"key":"73108_CR61","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s12013-013-9750-1","volume":"68","author":"M Akram","year":"2014","unstructured":"Akram, M. Citric acid cycle and role of its intermediates in metabolism. Cell Biochem. Biophys. 68, 475\u2013478. https:\/\/doi.org\/10.1007\/s12013-013-9750-1 (2014).","journal-title":"Cell Biochem. Biophys."},{"key":"73108_CR62","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1359-6446(01)01774-3","volume":"6","author":"DJ Payne","year":"2001","unstructured":"Payne, D. J., Warren, P. V., Holmes, D. J., Ji, Y. & Lonsdale, J. T. Bacterial fatty-acid biosynthesis: a genomics-driven target for antibacterial drug discovery. Drug Discov. Today 6, 537\u2013544 (2001).","journal-title":"Drug Discov. Today"},{"key":"73108_CR63","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1128\/AAC.02182-12","volume":"57","author":"NN Mishra","year":"2013","unstructured":"Mishra, N. N. & Bayer, A. S. Correlation of cell membrane lipid profiles with daptomycin resistance in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 57, 1082\u20131085 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"73108_CR64","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1128\/AAC.00432-10","volume":"56","author":"S Mehta","year":"2012","unstructured":"Mehta, S. et al. VraSR two-component regulatory system contributes to mprF-mediated decreased susceptibility to daptomycin in in vivo-selected clinical strains of methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 56, 92\u2013102 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"73108_CR65","doi-asserted-by":"crossref","first-page":"e107426","DOI":"10.1371\/journal.pone.0107426","volume":"9","author":"NN Mishra","year":"2014","unstructured":"Mishra, N. N. et al. Phenotypic and genotypic characterization of daptomycin-resistant methicillin-resistant Staphylococcus aureus strains: relative roles of mprF and dlt operons. PLoS ONE 9, e107426 (2014).","journal-title":"PLoS ONE"},{"key":"73108_CR66","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1089\/mdr.2017.0156","volume":"24","author":"SJ Yang","year":"2018","unstructured":"Yang, S. J. et al. Impact of multiple single-nucleotide polymorphisms within mprF on daptomycin resistance in Staphylococcus aureus. Microb. Drug Resist. 24, 1075\u20131081 (2018).","journal-title":"Microb. Drug Resist."},{"key":"73108_CR67","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3389\/fmicb.2018.01086","volume":"9","author":"FJ Chen","year":"2018","unstructured":"Chen, F. J. et al. Effect of a point mutation in mprF on susceptibility to daptomycin, vancomycin, and oxacillin in an MRSA clinical strain. Front Microbiol. 9, 1086 (2018).","journal-title":"Front Microbiol."},{"key":"73108_CR68","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.1128\/AAC.00417-08","volume":"52","author":"IL Camargo","year":"2008","unstructured":"Camargo, I. L., Neoh, H. M., Cui, L. & Hiramatsu, K. Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype. Antimicrob. Agents Chemother. 52, 4289\u20134299 (2008).","journal-title":"Antimicrob. Agents Chemother."},{"key":"73108_CR69","doi-asserted-by":"crossref","first-page":"6983","DOI":"10.1128\/AAC.01303-15","volume":"59","author":"KT B\u00e6k","year":"2015","unstructured":"B\u00e6k, K. T. et al. Stepwise decrease in daptomycin susceptibility in clinical Staphylococcus aureus isolates associated with an initial mutation in rpoB and a compensatory inactivation of the clpX gene. Antimicrob. Agents Chemother. 59, 6983\u20136991 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"73108_CR70","doi-asserted-by":"crossref","first-page":"683450","DOI":"10.1155\/2012\/683450","volume":"2012","author":"NN Mishra","year":"2012","unstructured":"Mishra, N. N., Rubio, A., Nast, C. C. & Bayer, A. S. Differential adaptations of methicillin-resistant Staphylococcus aureus to serial in vitro passage in daptomycin: evolution of daptomycin resistance and role of membrane carotenoid content and fluidity. Int. J. Microbiol. 2012, 683450 (2012).","journal-title":"Int. J. Microbiol."},{"key":"73108_CR71","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1128\/AAC.00223-11","volume":"55","author":"NN Mishra","year":"2011","unstructured":"Mishra, N. N. et al. In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 55, 4012\u20134018 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"key":"73108_CR72","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1128\/AAC.01454-12","volume":"57","author":"TT Tran","year":"2013","unstructured":"Tran, T. T. et al. Whole-genome analysis of a daptomycin-susceptible Enterococcus faecium strain and its daptomycin-resistant variant arising during therapy. Antimicrob. Agents Chemother. 57, 261\u2013268 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"73108_CR73","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1128\/AAC.01318-12","volume":"56","author":"RM Humphries","year":"2012","unstructured":"Humphries, R. M. et al. Genotypic and phenotypic evaluation of the evolution of high-level daptomycin nonsusceptibility in vancomycin-resistant Enterococcus faecium. Antimicrob. Agents Chemother. 56, 6051\u20136053 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"73108_CR74","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1099\/mic.0.26731-0","volume":"150","author":"V Vadyvaloo","year":"2004","unstructured":"Vadyvaloo, V., Snoep, J. L., Hastings, J. W. & Rautenbach, M. Physiological implications of class IIa bacteriocin resistance in Listeria monocytogenes strains. Microbiology 150, 335\u2013340 (2004).","journal-title":"Microbiology"},{"key":"73108_CR75","doi-asserted-by":"crossref","first-page":"e0150907","DOI":"10.1371\/journal.pone.0150907","volume":"11","author":"M Prax","year":"2016","unstructured":"Prax, M., Mechler, L., Weidenmaier, C. & Bertram, R. Glucose augments killing efficiency of daptomycin challenged Staphylococcus aureuspersisters. PLoS ONE 11, e0150907 (2016).","journal-title":"PLoS ONE"},{"key":"73108_CR76","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1128\/AEM.02542-10","volume":"77","author":"JC Cameron","year":"2011","unstructured":"Cameron, J. C. & Pakrasi, H. B. Glutathione facilitates antibiotic resistance and photosystem I stability during exposure to gentamicin in cyanobacteria. Appl. Environ. Microbiol. 77, 3547\u20133550 (2011).","journal-title":"Appl. Environ. Microbiol."},{"key":"73108_CR77","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1128\/AAC.01473-13","volume":"57","author":"C Miller","year":"2013","unstructured":"Miller, C. et al. Adaptation of Enterococcus faecalis to daptomycin reveals an ordered progression to resistance. Antimicrob. Agents Chemother. 57, 5373\u20135383 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"73108_CR78","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1128\/AAC.02470-13","volume":"58","author":"M Saito","year":"2014","unstructured":"Saito, M. et al. \u201cSlow VISA,\u201d a novel phenotype of vancomycin resistance, found in vitro in heterogeneous vancomycin-intermediate Staphylococcus aureus strain Mu3. Antimicrob. Agents Chemother. 58, 5024\u20135035 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"73108_CR79","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1128\/JCM.01128-10","volume":"49","author":"SW Satola","year":"2011","unstructured":"Satola, S. W., Farley, M. M., Anderson, K. F. & Patel, J. B. Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus with the population analysis profile method as the reference method. J. Clin. Microbiol. 49, 177\u2013183 (2011).","journal-title":"J. Clin. Microbiol."},{"key":"73108_CR80","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1128\/AAC.01173-08","volume":"53","author":"L Cui","year":"2009","unstructured":"Cui, L., Neoh, H. M., Shoji, M. & Hiramatsu, K. Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 53, 1231\u20131234 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"key":"73108_CR81","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mimet.2018.01.006","volume":"146","author":"Y Sato'o","year":"2018","unstructured":"Sato\u2019o, Y. et al. Optimized universal protocol for electroporation of both coagulase-positive and -negative Staphylococci. J. Microbiol. Methods 146, 25\u201332 (2018).","journal-title":"J. Microbiol. Methods"},{"key":"73108_CR82","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/jac\/42.2.199","volume":"42","author":"H Hanaki","year":"1998","unstructured":"Hanaki, H. et al. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J. Antimicrob. Chemother. 42, 199\u2013209 (1998).","journal-title":"J. Antimicrob. Chemother."},{"key":"73108_CR83","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1128\/AAC.44.9.2276-2285.2000","volume":"44","author":"L Cui","year":"2000","unstructured":"Cui, L., Murakami, H., Kuwahara-Arai, K., Hanaki, H. & Hiramatsu, K. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob. Agents Chemother. 44, 2276\u20132285 (2000).","journal-title":"Antimicrob. Agents Chemother."},{"key":"73108_CR84","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.carbpol.2016.09.075","volume":"157","author":"D Raafat","year":"2017","unstructured":"Raafat, D. et al. Development of in vitro resistance to chitosan is related to changes in cell envelope structure of Staphylococcus aureus. Carbohyd. Polym. 157, 146\u2013155 (2017).","journal-title":"Carbohyd. Polym."},{"key":"73108_CR85","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1139\/y59-099","volume":"37","author":"EG Bligh","year":"1959","unstructured":"Bligh, E. G. & Dyer, W. J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37, 911\u2013917 (1959).","journal-title":"Can. J. Biochem. Physiol."},{"key":"73108_CR86","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ijantimicag.2013.10.001","volume":"43","author":"V Cafiso","year":"2014","unstructured":"Cafiso, V. et al. dltA overexpression: A strain-independent keystone of daptomycin resistance in methicillin-resistant Staphylococcus aureus. Int. J. Antimicrob. Agents 43, 26\u201331 (2014).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"73108_CR87","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1128\/AAC.04990-14","volume":"59","author":"AD Berti","year":"2015","unstructured":"Berti, A. D. et al. Heterogeneity of genetic pathways toward daptomycin nonsusceptibility in Staphylococcus aureus determined by adjunctive antibiotics. Antimicrob. Agents Chemother. 59, 2799\u20132806 (2015).","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73108-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73108-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73108-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T15:16:24Z","timestamp":1670339784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73108-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,30]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["73108"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-73108-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,30]]},"assertion":[{"value":"27 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16107"}}